RadNet Inc has been on quite the ride lately. If you've been watching the ticker, you know exactly what I mean. One day the stock is surging on a monster earnings beat, and the next, it’s drifting as the broader market digests interest rate jitters. Honestly, trying to pin down the RadNet Inc stock price today feels a bit like trying to track a moving target in a windstorm.
As of mid-January 2026, we’re seeing the stock hover around the $73.32 mark. It's been a volatile start to the year. Just a week ago, it was pushing toward $78, flirting with those recent highs. But then, as it often does, the market took a breather. The 52-week range is a massive spread—from a low of roughly **$45.00** to a peak near $85.84. That is a lot of ground covered in twelve months.
What’s Actually Driving the Price Right Now?
It isn't just about how many MRIs they’re doing in California anymore. Sure, the core business is huge. They operate over 400 centers. That’s a massive footprint. But the real "secret sauce" people are whispering about is DeepHealth.
DeepHealth is RadNet's dedicated digital health arm. They are going all-in on AI. We aren't talking about "AI" as a buzzword used to fluff up a slide deck. They are actually implementing it to read scans faster and more accurately. In late 2025, they unveiled a whole new suite of informatics at the RSNA conference. They even signed a deal with GE HealthCare to bake this tech into more machines.
Investors love this because it changes the math. Traditional imaging is a volume game—you need more machines and more people to make more money. AI changes that. If an algorithm can help a radiologist work 20% faster, the margins explode. In the third quarter of 2025, their Digital Health revenue jumped over 50%. That is a staggering number for a healthcare company.
📖 Related: TCPA Shadow Creek Ranch: What Homeowners and Marketers Keep Missing
The Earnings Reality Check
While the growth looks great on paper, the bottom line has been... complicated.
RadNet reported an adjusted EPS of $0.20 for Q3 2025. They missed the analyst consensus of $0.23 by a hair. The market didn't love the miss, but they did love the revenue. Total revenue hit **$522.9 million**, which was way higher than what the street expected. It’s this constant tug-of-war between high spending on expansion and the actual profit hitting the bank account.
Most analysts are still bullish. About 83% of them have a "Buy" rating on the stock right now. The average price target is sitting somewhere around $91.75. If that holds true, we're looking at a decent upside from where we are today. But you've gotta remember that healthcare is sensitive. Medicare reimbursement changes can happen overnight and wipe out a forecast. It's the risk you take in this sector.
Why the $70 Support Level Matters
Technical traders are obsessed with the $70 to $72 range for RDNT. Whenever the RadNet Inc stock price dips toward that level, buyers seem to step in. It’s become a psychological floor.
👉 See also: Starting Pay for Target: What Most People Get Wrong
- Volume Trends: We saw a massive 22% surge back in August 2025 after a major earnings beat. That set a new "normal" for the stock's valuation.
- Institutional Interest: Big players aren't just day trading this. They see the shift toward outpatient care. Hospitals are expensive; RadNet is the "value" alternative for insurers.
- The Debt Load: They have a decent amount of cash—over $800 million at last check—but they also carry debt from all those acquisitions (like the recent CIMAR UK deal).
The next big catalyst is the Q4 earnings report, expected around February 26, 2026. That’s the date everyone has circled in red. If they can show that the AI integrations are actually lowering costs, the stock might finally break out of this $70-$80 consolidation zone.
The Misconception About "Just an Imaging Company"
People think RadNet is just a place you go when you tweak your knee playing pickleball. That’s the old story. The new story is a data company. Think about the millions of scans they own. In the age of machine learning, that data is gold. They are training their own models on their own data.
Howard Berger, the CEO, has been pretty vocal about this. He’s pushing the company to be a "technology-enabled" service provider. It's a subtle shift in wording, but a massive shift in how the stock is valued. If they’re a tech company, they get a tech multiple. Right now, the P/E ratio is sky-high—actually, it’s technically negative or highly distorted because of one-time costs and aggressive reinvestment.
Actionable Insights for Your Watchlist
If you're looking at RadNet as a potential addition to your portfolio, you shouldn't just look at the daily price action. It’s too noisy.
✨ Don't miss: Why the Old Spice Deodorant Advert Still Wins Over a Decade Later
Instead, watch the Digital Health segment revenue. If that continues to grow at 30-50% YoY, the stock price will eventually follow. Also, keep an eye on "same-center" growth. This tells you if their existing locations are getting more efficient or if they’re just growing by buying up competitors. In 2025, same-center MRI volume was up over 11%. That’s a healthy sign of organic demand.
Pay attention to the February earnings call. Specifically, listen for updates on the GE HealthCare partnership. If they start rolling out remote scanning solutions (Alpha RT assets), it could solve the radiologist shortage problem that plagues the whole industry.
The RadNet Inc stock price is currently caught between the reality of being a brick-and-mortar clinic operator and the potential of being an AI healthcare leader. It’s a transition phase. Transitions are usually messy, but they’re also where the biggest opportunities hide.
Monitor the $71 support level closely. If it holds through the end of January, the path to $85 looks a lot clearer. Conversely, a drop below $68 might signal that the market is losing patience with the "AI pivot" and wants to see more cold, hard profit.
Set a price alert for the $72.50 level. If it hits that and bounces on high volume, it might be a signal that the consolidation is ending. Review the Q3 10-Q filing to see the specific breakdown of their $804 million cash pile and how much is earmarked for further AI acquisitions versus debt servicing. Lastly, track the "Advanced Imaging" mix; as PET/CT and MRI scans make up a larger percentage of their total volume, the average revenue per scan climbs, which is the fastest way to boost the bottom line without building new buildings.